K. Koch

Characterization of the pharmacological profile of the potent LTB4 antagonist CP‐105,696 on murine LTB4 receptors in vitro.

M. Conklyn, H. Showell, R. Breslow, 1996, British journal of pharmacology.

(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.

A. Milici, E. Pettipher, L. Melvin, 1994, Journal of medicinal chemistry.

The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.

M. Smith, A. Milici, E. Pettipher, 1998, The Journal of pharmacology and experimental therapeutics.

Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.

M. Smith, A. Milici, E. Pettipher, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Orthopaedics and Haemophilia

M. Blombäck, G. Lüchters, F. Mandelli, 1981 .

Design and Synthesis of a Series of l-trans-4-Substituted Prolines as Selective Antagonists for the Ionotropic Glutamate Receptors Including Functional and X-ray Crystallographic Studies of New Subtype Selective Kainic Acid Receptor Subtype 1 (GluK1) Antagonist (2S,4R)-4-(2-Carboxyphenoxy)pyrrolidin

J. Kastrup, L. Bunch, D. Bowie, 2017, Journal of medicinal chemistry.